Series: The T Files — Series 4: “Gels, Patches & the Skin Transfer Disaster"
Subtitle: The transdermal era promised to fix everything. Then men started accidentally hormoning their wives.
Post: 2 of 5
Tags: Androderm, transdermal patch, testosterone, skin irritation, permeation enhancers, pruritus, TRT history, FDA approval 1995
Word Count: ~1,100
If the scrotal patch’s problem was anatomical — not enough skin, too much application awkwardness — the solution seemed obvious. Find a way to get testosterone through regular skin. Skin you could find on the back, the abdomen, the upper arms, the thighs. Skin that was plentiful, easily accessible, and mercifully unconnected to the application anxieties that sank the scrotal approach.
The result was Androderm, a non-scrotal transdermal testosterone patch developed by TheraTx (later acquired by Actavis) and approved by the FDA in 1995. It worked. It really did work — it maintained physiological testosterone levels, it mimicked the natural circadian rhythm, it required no hair clipping, and it could be applied to four different body sites.
It also caused skin blistering, itching, and irritation in approximately 48% of patients — nearly half of everyone who used it. The reason is directly traceable to the chemistry that made non-scrotal delivery possible in the first place.
The Permeation Enhancer Problem
Recall from the previous post: scrotal skin is roughly five times more permeable to testosterone than non-scrotal skin. The stratum corneum — the outermost skin barrier — is significantly thicker in non-genital areas of the body. Testosterone, a lipophilic steroid molecule, crosses the thinner scrotal stratum corneum reasonably well. Getting it through regular arm or back skin in therapeutically meaningful quantities requires help.
That help comes in the form of permeation enhancers: compounds added to the transdermal formulation specifically to increase skin permeability. They work by temporarily disrupting the orderly structure of the stratum corneum — loosening the tight lipid packing that normally keeps things out — to allow the drug to pass through at higher rates.
Common permeation enhancers used in transdermal pharmaceutical formulations include compounds like glycol salicylate, fatty acids, and surfactants. They are pharmacologically inert in the sense that they don’t have therapeutic effects of their own. But they are not biologically inert in the sense of being completely harmless to skin. The same mechanism by which they increase permeability — disrupting the stratum corneum — also creates a localized inflammatory response in a significant proportion of patients.
For Androderm, the clinical data are documented in the product labeling: combined clinical trial data report the overall incidence of any application site reactions as 48%, with pruritus (itching) being the most common adverse effect.
The Clinical Profile of Androderm
To understand what 48% means experientially, some context on the patch’s dosing and application protocol is helpful.
Androderm is available in 2 mg/day and 4 mg/day formulations. The recommended starting dose is one 4 mg/day patch applied nightly. Application sites include the back, abdomen, upper arms, or thighs. The patch must be applied to a different site each night — the same site cannot be reused for 7 days — which limits the rotation schedule. Dose escalation to 6 mg/day (one 4 mg + one 2 mg patch) is indicated for patients with testosterone levels below 400 ng/dL at two-week follow-up; reduction to 2 mg/day is indicated for levels above 930 ng/dL.
The pharmacokinetics are genuinely good. From the comparative trial by Dobs et al. (1999) — a 24-week, randomized comparison of the transdermal system against testosterone enanthate injections in 33 subjects per group — baseline serum testosterone of 55.4 ng/mL increased to an average of 517 ng/dL with the patch. Peak serum testosterone (Cmax) reached 765 ng/dL within 8.2 hours of application. The patch provided continuous absorption for 24 hours with no dose accumulation, closely mimicking the normal circadian testosterone pattern when applied nightly. The approximate half-life of the delivered testosterone is 1.3 hours, and hypogonadal concentrations return within 24 hours of patch removal — making it rapidly reversible if problems arise.
Compare that profile to testosterone enanthate’s supraphysiological spike to >1,200 ng/dL followed by subtherapeutic troughs. The patch’s pharmacokinetics are, by any reasonable assessment, dramatically more physiological.
Which makes the 48% skin reaction rate all the more frustrating.
What 48% Actually Looks Like
Nearly half of Androderm users experiencing any application site reaction is a number that requires some interpretation. “Any reaction” includes mild cases — transient redness, mild itching — that patients tolerate without discontinuing. But the distribution of severity matters.
Pruritus was the most frequently reported symptom. Erythema (redness), blistering, and localized vesiculation (fluid-filled skin blisters) were also documented adverse effects. For patients who developed vesicular blistering at the application site, the experience was not tolerable — and many discontinued.
The management recommendation in the Androderm package insert acknowledges the problem directly: topical corticosteroid application to the affected area is recommended for alleviation of symptoms. This is a somewhat remarkable product instruction — you apply the patch, your skin reacts, you manage the skin reaction with a separate topical steroid — that highlights how the tolerability problem was handled as a clinical management issue rather than a formulation problem.
Some patients were prescribed short courses of topical hydrocortisone or stronger corticosteroids to apply to application sites before or after the patch, which reduced the reaction severity. This worked to an extent. It also added a step to the daily routine of a therapy that was already daily.
The Efficacy/Tolerability Tension
Androderm illustrated a tension that would recur throughout transdermal testosterone development: pharmacokinetic success and patient experience success are not the same thing.
The clinical efficacy of Androderm was well-established. Testosterone levels were maintained in the physiological range. The circadian rhythm was approximated. The injection rollercoaster was avoided. From the purely pharmacological standpoint, the patch achieved what it was designed to achieve.
But a 48% skin reaction rate created a real-world adherence problem that compromised those pharmacokinetic advantages. A patch that requires daily application to a site rotation schedule, causes itching and blistering in nearly half of users, and may require concurrent management with topical steroids is a patch that a substantial proportion of patients will eventually stop using — regardless of how good the serum testosterone levels look on a blood draw.
The Path to Something Better
The Androderm experience established the design parameters for the next generation of transdermal testosterone products. What was needed was a delivery vehicle that could:
1. Get testosterone through non-scrotal skin without requiring permeation enhancers potent enough to cause widespread skin irritation
2. Maintain the continuous delivery profile that patches demonstrated
3. Allow for dose flexibility
4. Be tolerable enough for daily long-term use
The hydroalcoholic gel formulation — in which testosterone is dissolved in an ethanol/water carrier that evaporates rapidly after application, leaving testosterone to penetrate the skin — met most of these criteria. AndroGel arrived in the United States in 2000, and it changed the TRT landscape rapidly.
The gel era brought dramatic improvements in tolerability. It brought convenient daily application. It brought dose-adjustable, flexible products. It also brought a new problem that no one had anticipated when the patch era began: the testosterone was absorbed by the intended patient, but it could also be absorbed by anyone else who touched the application site. Wives. Children. Partners. And the consequences, in some of those cases, were significant enough to trigger a federal regulatory action.
Next time: AndroGel launched in 2000 and became the dominant form of TRT in the United States within a few years. We look at why it worked, what made it better than patches, and the specific pharmacokinetic data that made hydroalcoholic gels a genuine therapeutic advance.
